

December 8, 2025

RE: **2026 IOTOX Symposium: Delivering What Matters - Patient-Centered through IOTOX Translational Science**  
The University of Texas MD Anderson Cancer Center  
Zayed Building, Floor 2  
6565 MD Anderson Boulevard  
Houston, TX 77030

Dear Potential Exhibitor:

On behalf of **The University of Texas MD Anderson Cancer Center** and **Activity Director, Bilal A. Siddiqui, MD**, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine and **Co-Directors, Kristen E. Pauken, PhD**, Assistant Professor, Department of Immunology, Division of Discovery Science, and **Ajay Sheshadri, MD**, Associate Professor, Department of Pulmonary Medicine, Division of Internal Medicine, we would like to invite you to exhibit at our upcoming **2026 IOTOX Symposium: Delivering What Matters - Patient-Centered through IOTOX Translational Science**, scheduled for **April 24 – 25, 2026** at the **Zayed Building in Houston, Texas**. We offer a variety of exhibitor packages for your consideration, each designed to provide unique opportunities for participation.

## OVERVIEW

This symposium is designed to foster multidisciplinary collaboration among oncologists, internists, advanced practice providers, nurses, and pharmacists who manage patients experiencing immune-related adverse events (irAEs). Rapid advances in immuno-oncology have revolutionized cancer therapy, but they have also introduced complex and often unpredictable toxicities that span multiple organ systems. This program will highlight the latest evidence, clinical guidelines, and diagnostic tools to help healthcare professionals identify, manage, and prevent immune-mediated toxicities effectively. Through expert-led sessions, case-based discussions, and interactive problem-solving, attendees will gain actionable insights that translate emerging science into safe, coordinated, and patient-centered care.

## NEEDS ASSESSMENT

The accelerating adoption of immuno-oncology therapies has brought unprecedented advances in cancer care, particularly in extending patient survival and improving quality of life. Yet, these therapies also present healthcare professionals with complex toxicity profiles—including immune-related adverse events (irAEs)—that span multiple organ systems and frequently require sophisticated, interdisciplinary management. The rapid pace of research and clinical innovation in this field has resulted in persistent gaps in recognition, diagnosis, and evidence-based management of immunotherapy toxicities among oncologists, internists, pharmacists, and nurses.

Recent national and international guidelines provide frameworks for optimal care, but implementation remains inconsistent across clinical settings, particularly outside major academic centers. Many practitioners lack current knowledge about the mechanisms and management of irAEs, resulting in variation in treatment quality, delayed interventions, and compromised patient outcomes. In addition, multidisciplinary teamwork—essential for effective management—remains underdeveloped, with many clinicians expressing limited competence and confidence in coordinating care across specialties.

This educational activity responds to these critical gaps by convening oncology and internal medicine experts to share best practices, the latest clinical evidence, and real-world problem-solving strategies for immunotherapy toxicity management. The symposium will facilitate dialogue, foster team-based learning, and equip participants with evidence-backed tools for guideline-based care—all consistent with industry-supported CME requirements for independence, scientific rigor, and measurable outcomes. By directly addressing these professional practice, knowledge, competence, and performance gaps, this program aims to improve both provider expertise and patient safety, supporting the highest standards of unbiased continuing medical education.

## PROFESSIONAL PRACTICE GAP

Despite the growing use of immune checkpoint inhibitors and other immunotherapies, there remains limited standardization in the recognition and management of treatment-related toxicities. Variability exists across institutions and specialties in how care teams diagnose, stage, and treat irAEs. This inconsistency can delay intervention and compromise patient outcomes. The symposium directly addresses this practice gap by aligning multidisciplinary providers with current best practices and collaborative pathways for the management of immunotherapy-related toxicities.

## KNOWLEDGE GAP

Healthcare professionals often lack up-to-date knowledge on evolving immunotherapy mechanisms, toxicity profiles, and current evidence-based management strategies. With new agents entering clinical use at a rapid pace, gaps persist in understanding the underlying immunopathophysiology and in applying consensus guidelines from national oncology and subspecialty organizations. The symposium will close this gap by delivering current data, clinical algorithms, and real-world examples to reinforce foundational and advanced knowledge in immunotherapy toxicity management.

## COMPETENCE GAP

Effectively caring for patients with immunotherapy-related toxicities requires an integrated approach among oncology, primary care, and specialty services. Many clinicians feel uncertain about when to escalate care, initiate immunosuppressive therapy, or coordinate multidisciplinary interventions. This symposium enhances clinical competence by offering structured decision-making frameworks, peer discussion, and expert-led case simulations that help participants confidently manage complex scenarios, ensuring timely, appropriate, and evidence-aligned patient care.

## PERFORMANCE GAP

Current performance across health systems indicates inconsistent application of management protocols and limited coordination among care teams treating irAEs. This can result in unnecessary treatment interruptions, higher morbidity, and fragmented follow-up care. By reinforcing standardized approaches and team-based communication strategies, the symposium supports measurable improvements in clinical performance. Participants will leave equipped with tools, checklists, and integrated care pathways that drive consistent, high-quality management of immunotherapy toxicities within their practice settings.

## OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Develop treatment plans that follow current guidelines for managing immunotherapy toxicities.
- Find and use national society recommendations to guide care decisions.
- Apply ITOX guidelines that have been reviewed and approved by both oncologists and internal medicine experts.
- Evaluate complex patient cases and tailor treatment plans to meet individual needs.
- Use ITOX protocols across the care team to ensure coordinated and effective care.

## TARGET AUDIENCE

Specialties - Internal Medicine

Professions - Nurse - APRN, LVN, RN, Other, Pharmacist, Physician (MD or DO), Physician Associate, Student or Trainee

### Satellite Symposium – \$15,000

A 45-minute informational presentation and discussion by industry representatives and others speaking on behalf of their company offers healthcare providers with valuable scientific and clinical information about medicines that may lead to improved patient care. Satellite Symposiums provide the platform for these valuable presentations. Please review the following for important information. If your company is interested, you may choose one slot from the following four available options.

OPTION 1	
Lunch Symposium	Date: Friday, April 24, 2026 Time: 12:30 – 1:15 pm
OPTION 2	
Lunch Symposium	Date: Saturday, April 25, 2026 Time: 11:45 – 12:30 pm

## Presentation Information

Satellite Symposium are promotional presentations that highlight a new service or provide material about product development. A Satellite Symposium should be appropriate and professional, as well as focus on the science related to the development of product or of a service provided by the company.

Satellite Symposium sponsors are not permitted to certify the Satellite Symposium by a CE Provider and must submit faculty and topics to CPE for approval.

Submit the following information by **Monday, April 6, 2026**, to [rpdavis@mdanderson.org](mailto:rpdavis@mdanderson.org)

- Title of Presentation for the Satellite Symposium Presentation
- Name, Title, Credentials and contact information of the speaker/faculty
- Two bullet points that provide a description of the Satellite Symposium topic

A Satellite Symposium sponsor is responsible for the content of its presentation, including obtaining all appropriate copyright permissions and licenses for slides and other materials that will be presented or distributed.

## Satellite Symposiums Accepted

A completed agreement, with full payment are accepted for Satellite Symposiums on a first-come, first-served basis.

## EXHIBIT OPPORTUNITIES

---

### PLATINUM – \$10,000

- Five Complimentary Registrations
- Five complimentary reception tickets – Friday, April 24<sup>th</sup> at 5:30 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website, and the ability to post 3 – 6 product information (pdfs)
- Designated premium location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Platinum level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### GOLD – \$7,500

- Four Complimentary Registrations
- Four complimentary reception tickets – Friday, April 24<sup>th</sup> at 5:30 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website
- Designated premium location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Gold level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### SILVER – \$5,000

- Three Complimentary Registrations
- Three complimentary reception tickets – Friday, April 24<sup>th</sup> at 5:30 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name and link to company website
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Silver level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### BRONZE – \$2,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Friday, April 24<sup>th</sup> at 5:30 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

### NON-PROFIT – \$1,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Friday, April 24<sup>th</sup> at 5:30 pm
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- Networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

---

### CONFERENCE LOCATION

The University of Texas MD Anderson Cancer Center  
Zayed Building, Floor 2  
6565 MD Anderson Boulevard  
Houston, TX 77030

### CONFERENCE TIMES

Friday, April 24, 2026	Saturday, April 25, 2026
Set-Up: 11:30 – 12:30 PM	Set-Up: 7:00 – 7:30 AM
Check-in/Lunch: 12:30 PM	Check-in/Breakfast: 7:30 AM
Conference: 1:30 – 5:30 PM	Conference: 8:00 AM – 3:35 PM
Dismantle: 5:30 PM	Dismantle: 2:30 PM

### REGISTER

[Please Click Here for More Information or To Register.](#)

To register as an exhibitor, click on the Exhibitor tab, select Exhibit at this Event

Please note: Registration and an exhibit agreement are necessary to participate as an exhibitor. The exhibit is not considered confirmed until your company has registered, and we have a fully executed agreement. The agreement and payment should be received prior to the activity.

Please let me know if you have any questions or need any additional information for this request. We appreciate your consideration to participate as an exhibitor at this exceptional educational activity.

I look forward to hearing from you soon.

Best,

**Robyn P. Davis**

Senior Continuing Education Coordinator  
Continuing Professional Education  
The University of Texas MD Anderson Cancer Center

# 2026 IOTOX SYMPOSIUM

Delivering What Matters:  
Patient-centered Outcomes Through IOTOX Translational Science

Apr. 24-25, 2026 | Zayed Building or via Zoom | [Register here](#)

THE UNIVERSITY OF TEXAS  
**MD Anderson**  
**Cancer Center**  
Making Cancer History\*

## Friday, April 24

### Session 1: Welcome and Keynote Address

1:30 – 1:35 pm

#### Welcome Remarks (Overview & Introduction of Keynote Speaker)

David Tweardy, MD, Professor, Infectious Diseases, Division Head of Internal Medicine

1:35 – 2:30 pm

#### Keynote Address:

TBD

### Session 2: Clinical Perspectives to Scientific Discovery: Integrating Care and Research in Immune-Mediated Pneumonitis

**Moderators:** Mehmet Altan, MD, Associate Professor, Thoracic- Head & Neck Med Onc  
Seyed Moghaddam, MD, Professor, Pulmonary Medicine

2:30 – 3:00 pm

#### Clinical Management and Current Limitations in Treatment

Ajay Sheshadri, MD, Associate Professor, Pulmonary Medicine

3:00 – 3:30 pm

#### Steroid-refractory Pneumonitis

Kevin Ho, MD, Assistant Professor, Ohio State University

3:30 – 3:45 pm

#### Break and Networking

3:45 – 4:15 pm

#### ICT Pneumonitis: Novel Mechanisms and Potential Therapy

Jianjun Gao, MD, PhD, Professor, Genitourinary Medical Oncology

4:15 – 4:45 pm

#### Radiomic Imaging - TBD

Jia Wu, PhD, Associate Professor, Imaging Physics

4:45 – 5:30 pm

#### Panel Discussion

5:30 – 6:30 pm

### Session 3: Poster Presentations and Welcome Reception

## Join us

#### Physical location:

Zayed Building  
6565 MD Anderson Blvd., Houston, TX

Join virtually: [Link coming soon](#)

## Post-event Survey

After the event, we invite  
you to complete this  
feedback survey.

## Saturday, April 25

### Session 4: Day 2 Welcome and Keynote Address

#### Welcome Remarks (Overview & Introduction of Keynote Speaker)

**Christopher Flowers, MD**, Professor, Lymphoma-Myeloma,  
Division Head of Cancer Medicine

#### Keynote Address:

**Douglas Johnson, MD**, Professor, Vanderbilt University

### Session 5: Round Table Discussions – Multi-Omics Bridging the Gap between Basic Science and Clinical Care

**Moderators:** Sumit Subudhi, MD, PhD, Associate Professor, Genitourinary Med Onc

#### Panelists - Physicians

**Catherine Sears, MD, PhD**, Assistant Professor, University of California at Los Angeles  
**Stephane Champiat, MD**, Associate Professor, Investigational Cancer Therapeutics  
**Sangeeta Goswami, MD**, Associate Professor, Genitourinary Med Onc

#### Panelists- Scientists

**Linghua Wang, PhD**, Associate Professor, Genomic Medicine  
**Kristen Pauken, PhD**, Assistant Professor, Immunology  
**Jason Schenkel, PhD**, Assistant Professor, Laboratory Medicine Admin

#### Topics to be discussed

- TBD
- TBD

#### Break and Networking

### Session 6: From Clinical Challenges to Research Innovations in irAEs I

**Moderators:** Yinghong Wang, MD, PhD, Professor, Gastroenterology & Hepatology  
Roza Nurieva, PhD, Professor, Immunology

#### Colitis irAEs

**Shilpa Grover, MBBS, MPH**, Associate Professor, Harvard Medical School

#### Liver irAEs

**John Vierling, MD**, Professor, Baylor College of Medicine

#### Derm irAEs

**Anisha Patel, MD**, Associate Professor, Dermatology

#### Lunch (Satellite Symposium from Sponsors)



## **Session 7: Clinical Challenges and Research Innovations in irAEs II**

**Moderators:** Joanna-Grace Manzano, MD, Associate Professor, Hospital Medicine  
Nicolas Palaskas, MD, Associate Professor, Cardiology

12:45 – 1:15 pm

### **Endocrine irAEs**

**Afreen Shariff, MD**, Associate Professor, Duke Cancer Institute

1:15 – 1:45 pm

### **Nephritis irAEs**

**Ala Abudayyeh, MD**, Professor, Nephrology

1:45 – 2:15 pm

### **Hematology irAEs**

**Thein Hlaing Oo, MD**, Professor, Benign Hematology

2:15 – 2:30 am

### **Break and Networking**

## **Session 8: Oral Abstract Presentations (Select from Abstract Submissions)**

**Moderators:** Fellow  
Postdoc

2:30 – 2:45 pm

### **Presentation 1**

2:45 – 3:00 pm

### **Presentation 2**

3:00 – 3:15 pm

### **Presentation 3**

3:15 – 3:30 pm

### **Presentation 4**

3:30 – 3:35 pm

## **Closing Remarks**

**Bilal Siddiqui, MD**, Assistant Professor, Genitourinary Med Oncology

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type.  
See Specific Instructions on page 3.

1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.)  
**The University of Texas MD Anderson Cancer Center**

2 Business name/disregarded entity name, if different from above.

3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only **one** of the following seven boxes.  

☐ Individual/sole proprietor    ☐ C corporation    ☐ S corporation    ☐ Partnership    ☐ Trust/estate

☐ LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) \_\_\_\_\_  
**Note:** Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.

☒ Other (see instructions)    **Agency within the Government of the State of Texas**

3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions \_\_\_\_\_ ☐  
**(Applies to accounts maintained outside the United States.)**

4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):  
Exempt payee code (if any)    **3**  
Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any)    **C**

5 Address (number, street, and apt. or suite no.). See instructions.  
**1515 Holcombe Boulevard**

6 City, state, and ZIP code  
**Houston, TX 77030**

7 List account number(s) here (optional)

Requester's name and address (optional)

**Part I Taxpayer Identification Number (TIN)**  
Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.  
**Note:** If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number  
\_\_\_\_ - \_\_\_\_ - \_\_\_\_\_  
or  
Employer identification number  
7 4 - 6 0 0 1 1 1 8

**Part II Certification**  
Under penalties of perjury, I certify that:  
1. The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and  
2. I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and  
3. I am a U.S. citizen or other U.S. person (defined below); and  
4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.  
**Certification instructions.** You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here  
Signature of U.S. person    **Omer F. Sultan**  
Date    **2/11/2025 | 9:47 AM CST**

**General Instructions**  
Section references are to the Internal Revenue Code unless otherwise noted.  
**Future developments.** For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9).  
**What's New**  
Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

**Purpose of Form**  
An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they